Atle Fund Management AB has filed a Form 13F-HR with the U.S. Securities and Exchange Commission, disclosing its equity securities portfolio as of the close of business on September 30, 2026. The filing was signed by Jeanette Kangur, the Chief Executive Officer of the Stockholm-based firm.
The report lists 39 distinct equity securities held by the fund at the end of the reporting period. The largest position disclosed in the filing is Eli Lilly & Co., with 36,103,210 shares. Other significant holdings include Thermo Fisher Scientific (23,228,471 shares), Intuitive Surgical (10,429,246 shares), and Merck & Co. (24,555,501 shares).
The portfolio includes a mix of large-cap pharmaceutical and technology companies, as well as several biotechnology firms. Notable biotechnology holdings include Vertex Pharmaceuticals (14,720,761 shares), BioGen (16,027,315 shares), and Revolutions Medicines (13,570,354 shares). The filing also lists several sponsored American Depositary Receipts (ADRs) from international companies, such as Alkermes PLC, BeOne Medicines, and Pathways PLC.
Atle Fund Management AB is headquartered at Riddargatan 23A in Stockholm, Sweden, and the filing indicates the report was prepared on November 12, 2026.
